Verition Fund Management
SUPN icon

Verition Fund Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Verition Fund Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-20,000
Closed -$474K – 1036
2019
Q4 		$474K Buy
+20,000
New +$486K 0.01% 686

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Verition Fund Management's SUPN Position: Q1 2026 in Review

Verition Fund Management sold out of Supernus Pharmaceuticals (SUPN) in Q1 2026, closing a stake of 12,501 shares — an estimated $621K sold.

Verition Fund Management first reported a position in SUPN in Q3 2014 and held it in 8 quarters. The position peaked at $1.19M in Q2 2019. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Verition Fund Management reported no remaining Supernus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 12,501 Supernus Pharmaceuticals shares in Q1 2026, an estimated $621K.
  • Verition Fund Management first reported a position in Supernus Pharmaceuticals in Q3 2014 and held it in 8 quarters.
  • Verition Fund Management's Supernus Pharmaceuticals position peaked at $1.19M in Q2 2019.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.